Дерматологические реакции, обусловленные действием противоопухолевых препаратов — ингибиторов рецепторов эпидермального фактора роста


Цитировать

Полный текст

Аннотация

Приведены данные литературы сведения о современных противоопухолевых препаратах, действующих как ингибиторы рецепторов эпидермального фактора роста, с чем связаны их неизбежные побочные реакции в виде кожной токсичности. Даны принципы терапевтических подходов к таким реакциям и приводится собственное наблюдение случая.

Об авторах

Екатерина Вадимовна Орлова

ГБУО ВПО Первый МГМУ им И.М.Сеченова Минздрава России

Email: kolip7@mail.ru
кандидат мед. наук Moscow, Russia

Ольга Юрьевна Олисова

ГБУО ВПО Первый МГМУ им И.М.Сеченова Минздрава России

Email: olisovaolga@mail.ru
доктор мед. наук, профессор Moscow, Russia

Людмила Юрьевна Севидова

ГБУО ВПО Первый МГМУ им И.М.Сеченова Минздрава России

кандидат мед. наук. Moscow, Russia

Николай Георгиевич Кочергин

ГБУО ВПО Первый МГМУ им И.М.Сеченова Минздрава России

Email: nkocha@yandex.ru
доктор мед. наук, профессор Moscow, Russia

Список литературы

  1. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999; 82(3): 241—50.
  2. Weiner L.M. Fully human therapeutic monoclonal antibodies. J. Immunother. 2006; 29(1): 1—9.
  3. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer. 2006; 6(10): 803—12.
  4. Douillard J.Y., Siena S., Cassidy J. Randomized, phase III study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): the PRIME trial. Eur. J. Cancer. 2009; 7(Suppl. 3): abstr.10LBA.
  5. Peeters M., Price T., Hotko Y. Randomized, phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC). Eur. J. Cancer. 2009; 7(Suppl. 3): abstr. 14LBA.
  6. Peeters M., Van Cutsem E., Siena S. et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. In: Program and abstracts of the 97th Annual Meeting of the American Association for Cancer Research. April 1—5 2006, Washington DC; Proc. Am. Assoc. Cancer Res. 2006; 47: abstr. CP-1.
  7. Mitchell E.P., Perez-Soler R., Van Cutsem E., Lacouture M.E. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park). 2007; 21(11, Suppl. 5): 4—9.
  8. Pilon M., Mailhot M., Comtois A. Evaluation of a protocol algorithm for the treatment of epidermal growth factor receptor inhibitors-induced dermatological side effects (Epiderm study). In: Presented at: 44th American Society of Clinical Oncology Annual Meeting. May 30—June 3, 2008; Chicago, IL. abstr. 20755.
  9. Ocvirk J., Rebersek M. Managing cutaneous side effects with K1 vitamine creme reduces cutaneous toxicities induced by cetuximab. In: Presented at 44th American Society of Clinical Oncology Annual Meeting. May 30—June 3, 2008; Chicago, IL. abstr. 20750.
  10. Activities of Daily Living. NCI-CTCAE V.4.0. http://ctep.cancer.gov.
  11. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist. 2006; 11(9): 1010—7.
  12. Lacouture M.E., Mitchell E.P., Piperdi B., Pillai M.V., Shearer H., Iannotti N., et al. Skin oxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010; 28(8): 1351—7. doi: 10.1200/JCO.2008.21.7828.
  13. Elez E., Macarulla T., Tabernero J. Handling side-effects of targeted therapies: safety of targeted therapies in solid timours. Ann. Oncol. 2008; 19(Suppl.7): vii146—52. doi: 10.1093/annonc/mdn476.
  14. Bosch J., Abella L., Viudez A., Chopitea A., Rodriguez J., Rodriguez J., et al. Clinical impact on time to progression (TTP) of acneiform skin lesions in cetuximab-based regimens in colorectal cancer. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2008; 26(15, Suppl.): abstr. 15096.
  15. O’Callaghan C.J., Tu D., Karapetis C.S., Au H.J., Moore M.J., Zalcberg J.R., et al. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2008; 26(15, Suppl.): abstr. 4130.
  16. Humblet Y., Peeters M., Siena S., Hendlisz A., Neyns B., Sobrero A., et al. Association of skin toxicity severity with clinical outcomes and health-related quality of life with panitumumab. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2007; 25 (18, Suppl.): abstr. 4038.
  17. Berlin J., Van Cutsem E., Peeters M., Hecht J.R., Ruiz R., Wolf M., et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2007; 25(18, Suppl.): abstr. 4134.
  18. Douillard J.Y., Cassidy J., Jassem J., Rivera F., Kocáková I., Rogowski W., et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2010; 28(15, Suppl., Pt 1): abstr. 3528. www.ejconline.com

© ООО "Эко-Вектор", 2013


 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах